Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2015

Collaboration Agreement [Abstract]

Collaboration revenue with related party

Sanofi collaboration revenue, as detailed below, consisted primarily of (i) recognition of previously deferred revenue related to the companies' ZALTRAP^® collaboration agreement, and (ii) reimbursement for research and development expenses that the Company incurred, partly offset by sharing of pre-launch commercialization expenses, in connection with the companies' antibody collaboration.

	Three Months Ended March 31,
Sanofi Collaboration Revenue	2015			2014
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	—			$	(3,212	)
Reimbursement of Regeneron research and development expenses	$	686		1,092
Other	15,236			2,177
Total ZALTRAP	15,922			57
Antibody:
Reimbursement of Regeneron research and development expenses	168,820			126,822
Reimbursement of Regeneron commercialization-related expenses	8,458			—
Regeneron's share of losses in connection with commercialization of antibodies	(22,405		)	—
Other	2,561			3,629
Total Antibody	157,434			130,451
	$	173,356		$	130,508

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three Months Ended March 31,
Bayer HealthCare Collaboration Revenue	2015		2014
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	89,426	$	61,159
Sales milestones	15,000		30,000
Cost-sharing of Regeneron EYLEA development expenses	2,657		20,347
Other	12,912		10,932
Total EYLEA	119,995		122,438
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	1,254		513
Other	2,597		2,361
Total PDGFR-beta	3,851		2,874
Total Bayer HealthCare collaboration revenue	$	123,846	$	125,312